The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

Karen Carrasquillo, OD, PhD, sat down with Optometry Times®' assistant managing editor Emily Kaiser to talk about her role on the founding board of Latinos en Optometry (LEO).

EverPatch is described by the company as the world's first non-degradable, synthetic tissue substitute for ophthalmic surgery.

The right nutrients can give your vision—and your game—an edge.

The trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.

How to diagnose and monitor progression.

Catch up on what happened in optometry during the week of June 5-June 9.

Prevent Blindness is embarking on a new strategy to raise awareness and provide education to patients and professionals to work together to address and improve the mental wellbeing for those with vision impairment.

The clinic, connected with Transitions Academy, aims to address the unmet needs of more than 80 local Pathlight HOME clients who may have otherwise lacked access to eye exams and glasses.

The water-free, preservative-free, anti-inflammatory drop from Novaliq, now coined Vevye, received FDA approval to treat the signs and symptoms of dry eye disease.

Comanagement optimizes outcomes for patients who wear scleral lenses.

The 126th annual American Optometric Association Optometry’s Meeting will convene in Washington, DC from June 21 to June 24, 2023.

The National Keratoconus Foundation has named NASCAR driver Joey Gase as Ambassador.

NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for patients ages 3 to 17.

Lattice retinal degeneration is the most significant peripheral retinal change associated with retinal detachment. Generally, it is a stable condition without symptoms unless the complication of a retinal tear develops, which can lead to retinal detachment. There are a number of presentations among patients, who can be of a young age and have almost any refractive correction.

Glenda Aleman Moheeputh, OD, president and CEO of OK Love Myopia Control Experts in Florida, sat down with Optometry Times®' editor Kassi Jackson to talk about her role on the founding board of Latinos en Optometry (LEO).

The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.

Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses leverage Bausch + Lomb’s proprietary lens tech to deliver all-day comfort and seamless transitions between near, intermediate, and distance vision for patients with presbyopia.

Lessons learned from the exam room.

Catch up on what happened in optometry during the week ofMay 29-June 2.